Holen Sie sich die Stockscreener-App
1.03
3.74%
-0.04
Schlusskurs vom Vortag:
$1.07
Offen:
$1.09
24-Stunden-Volumen:
1.28M
Relative Volume:
0.59
Marktkapitalisierung:
$166.67M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
25.75
EPS:
0.04
Netto-Cashflow:
$146.36M
1W Leistung:
+14.84%
1M Leistung:
+49.93%
6M Leistung:
-46.35%
1J Leistung:
-76.85%
1-Tages-Spanne:
$1.03
$1.11
1-Wochen-Bereich:
$0.81
$1.16
52-Wochen-Spanne:
$0.5271
$5.205
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Vergleichen Sie IRWD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
1.03 | 173.80M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
154.11 | 67.83B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.00 | 46.74B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.52B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.86 | 20.12B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
313.13 | 14.11B | 2.99B | 1.21B | 1.13B | 25.06 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-09 | Eingeleitet | Jefferies | Buy |
| 2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-02 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Eingeleitet | Northland Capital | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
| 2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
| 2017-04-07 | Bestätigt | Mizuho | Buy |
| 2017-02-22 | Bestätigt | Barclays | Equal Weight |
| 2016-11-04 | Bestätigt | Mizuho | Buy |
| 2016-10-24 | Bestätigt | Wedbush | Neutral |
| 2016-10-10 | Bestätigt | Mizuho | Buy |
| 2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
Multi factor analysis applied to Ironwood Pharmaceuticals Inc.2025 Earnings Surprises & Stepwise Trade Signal Implementation - Newser
Published on: 2025-08-15 04:45:17 - Newser
Can Ironwood Pharmaceuticals Inc. be recession proofJuly 2025 Catalysts & Safe Entry Momentum Tips - classian.co.kr
Ironwood Pharmaceuticals Inc. Uptrend in Early Stages Indicators Say YesJuly 2025 Summary & AI Enhanced Trading Signals - newsyoung.net
Published on: 2025-08-14 14:41:22 - beatles.ru
Sectors Driving Future Growth for Ironwood Pharmaceuticals Inc. StockWeekly Trend Report & Capital Efficiency Focused Strategies - Newser
Can Ironwood Pharmaceuticals Inc. expand its profit margins2025 Performance Recap & Verified Entry Point Detection - 선데이타임즈
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 89bio (ETNB), Relay Therapeutics (RLAY) and Ironwood Pharma (IRWD) - The Globe and Mail
Risk adjusted return profile for Ironwood Pharmaceuticals Inc. analyzedFree Swing Trading Plan With Smart Signals - Newser
Historical volatility pattern of Ironwood Pharmaceuticals Inc. visualizedJuly 2025 Momentum & Daily Profit Focused Screening - Newser
Volume spikes in Ironwood Pharmaceuticals Inc. stock – what they meanSmart Entry Signals for Active Traders - Newser
Short Bowel Syndrome Market to Experience Notable Growth - openPR.com
Short Bowel Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire, AbbVie, Hanmi Pharma - Barchart.com
How high can Ironwood Pharmaceuticals Inc. stock goSmart Entry Signals for Active Traders - Newser
Ironwood Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates - Yahoo Finance
Ironwood: Q2 Earnings Snapshot - Connecticut Post
Ironwood Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Ironwood (IRWD) Q2 EPS Jumps 600% - AOL.com
Ironwood Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ironwood Pharmaceuticals (IRWD.O) Surges 15.5% on Strong KDJ Signal Amid Mixed Peer Performance - AInvest
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance - BioSpace
Ironwood Pharmaceuticals Q2 2025 Earnings: EPS of $0.15 and Reve - GuruFocus
Ironwood Pharmaceuticals Tops Expectations With Strong Q2 Results - Finimize
Ironwood Pharmaceuticals (IRWD) Projected to Post Quarterly Earnings on Thursday - Defense World
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Ironwood Pharmaceuticals Inc expected to post earnings of 4 cents a shareEarnings Preview - TradingView
Custom Dashboard Highlights Ironwood Pharmaceuticals Inc. Price MomentumFundamental Growth Stock Analysis Shows Strength - beatles.ru
Published on: 2025-08-04 00:15:09 - Jammu Links News
What drives Ironwood Pharmaceuticals Inc. stock priceExpert guidance for superior capital growth - Jammu Links News
Is Ironwood Pharmaceuticals Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert guidance - Jammu Links News
Is it the right time to buy Ironwood Pharmaceuticals Inc. stockOutstanding risk-reward balance - Jammu Links News
Is Ironwood Pharmaceuticals Inc. a growth stock or a value stockDiscover stocks with strong growth potential - Jammu Links News
What are the technical indicators suggesting about Ironwood Pharmaceuticals Inc.Build a winning investment strategy - Jammu Links News
What are the latest earnings results for Ironwood Pharmaceuticals Inc.Unprecedented growth rates - Jammu Links News
What catalysts could drive Ironwood Pharmaceuticals Inc. stock higher in 2025Achieve breakthrough financial growth - Jammu Links News
How strong is Ironwood Pharmaceuticals Inc. company’s balance sheetDynamic portfolio growth - Jammu Links News
What makes Ironwood Pharmaceuticals Inc. stock price move sharplyExceptional financial outcomes - Jammu Links News
What Fibonacci levels say about Ironwood Pharmaceuticals Inc. reboundAutomated AI Forecast with Trading Alerts - Newser
Earnings visualization tools for Ironwood Pharmaceuticals Inc.Market Stability and Long-Term Growth Outlook - Newser
What is the risk reward ratio of investing in Ironwood Pharmaceuticals Inc. stockStock Market Picks With High Returns - Jammu Links News
Evaluating Ironwood Pharmaceuticals Inc. with trendline analysisSummary of Consistent Growth Stock Picks - Newser
How hedge fund analytics apply to Ironwood Pharmaceuticals Inc. stockAI Driven Buy Alert Trade Blueprint Released - metal.it
Exit strategy if you’re trapped in Ironwood Pharmaceuticals Inc.2025 Market Trends & Long Hold Capital Preservation Plans - Newser
Ironwood Pharmaceuticals Inc. Recovery Likely Here’s What Data ShowsReal Time Alerts Based on AI Prediction Triggered - metal.it
Heatmap Data Shows High Activity in Ironwood Pharmaceuticals Inc. SectorAccurate Buy Point for Momentum Stocks Detected - metal.it
What are Ironwood Pharmaceuticals Inc. company’s key revenue driversFree Stock Market Real-Time Monitoring - jammulinksnews.com
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ironwood Pharmaceuticals Inc-Aktie (IRWD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| John Minardo | Chief Legal Officer |
Aug 11 '25 |
Sale |
0.84 |
7,754 |
6,513 |
400,378 |
| Martini Gregory S. | Chief Financial Officer |
Aug 11 '25 |
Sale |
0.84 |
1,265 |
1,063 |
182,545 |
| Silver Ronald | Principal Accounting Officer |
Aug 11 '25 |
Sale |
0.84 |
2,846 |
2,391 |
276,809 |
2.80%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):